BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 18649370)

  • 21. IGF2BP1 harbors prognostic significance by gene gain and diverse expression in neuroblastoma.
    Bell JL; Turlapati R; Liu T; Schulte JH; Hüttelmaier S
    J Clin Oncol; 2015 Apr; 33(11):1285-93. PubMed ID: 25753434
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical significance of a highly sensitive analysis for gene dosage and the expression level of MYCN in neuroblastoma.
    Tanaka S; Tajiri T; Noguchi S; Shono K; Ihara K; Hara T; Suita S
    J Pediatr Surg; 2004 Jan; 39(1):63-8. PubMed ID: 14694373
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ultrahigh-risk group within the high-risk neuroblastoma category.
    Saarinen-Pihkala UM; Jahnukainen K; Wikström S; Koivusalo A; Karikoski R; Sariola H; Hovi L
    J Pediatr Hematol Oncol; 2013 Aug; 35(6):e254-9. PubMed ID: 23588329
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pulmonary metastases at diagnosis of neuroblastoma in pediatric patients: CT findings and prognosis.
    Kammen BF; Matthay KK; Pacharn P; Gerbing R; Brasch RC; Gooding CA
    AJR Am J Roentgenol; 2001 Mar; 176(3):755-9. PubMed ID: 11222220
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cyto-morphologic evaluation of bone marrow in infants with disseminated neuroblastoma.
    Sorrentino S; Rosanda C; Parodi S; Rita Gigliotti A; Pasino M; Defferrari R; Tonini GP; De Bernardi B
    J Pediatr Hematol Oncol; 2012 Mar; 34(2):154-8. PubMed ID: 22367387
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Locoregional MYCN-amplified neuroblastoma.
    Morales La Madrid A; Volchenboum S; Gastier-Foster JM; Pyatt R; Liu D; Pytel P; Lavarino C; Rodriguez E; Cohn SL
    Pediatr Blood Cancer; 2012 Oct; 59(4):736-8. PubMed ID: 22213566
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Subclassification and individual survival time prediction from gene expression data of neuroblastoma patients by using CASPAR.
    Oberthuer A; Kaderali L; Kahlert Y; Hero B; Westermann F; Berthold F; Brors B; Eils R; Fischer M
    Clin Cancer Res; 2008 Oct; 14(20):6590-601. PubMed ID: 18927300
    [TBL] [Abstract][Full Text] [Related]  

  • 28. MYCN gene amplification in patients with neuroblastic tumors.
    Estiar MA; Fazilaty H; Aslanabadi S; Seifi M; Varghaei P; Rezamand A
    Cell Mol Biol (Noisy-le-grand); 2014 Sep; 60(3):23-8. PubMed ID: 25231001
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Chromosome band 11q23 deletion predicts poor prognosis in bone marrow metastatic neuroblastoma patients without MYCN amplification.
    Yue ZX; Xing TY; Gao C; Liu SG; Zhao W; Zhao Q; Wang XS; Jin M; Ma XL
    Cancer Commun (Lond); 2019 Nov; 39(1):68. PubMed ID: 31685009
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Bilateral adrenal neuroblastoma.
    Pagès PM; Dufour C; Fasola S; Michon J; Boutard P; Gentet JC; Hartmann O
    Pediatr Blood Cancer; 2009 Feb; 52(2):196-202. PubMed ID: 18951434
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Association of CYP3A4/5 genotypes and expression with the survival of patients with neuroblastoma.
    Darwish MH; Farah RA; Farhat GN; Torbey PH; Ghandour FA; Bejjani-Doueihy NA; Dhaini HR
    Mol Med Rep; 2015 Feb; 11(2):1462-8. PubMed ID: 25370902
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Excellent outcome with reduced treatment in infants with nonmetastatic and unresectable neuroblastoma without MYCN amplification: results of the prospective INES 99.1.
    Rubie H; De Bernardi B; Gerrard M; Canete A; Ladenstein R; Couturier J; Ambros P; Munzer C; Pearson AD; Garaventa A; Brock P; Castel V; Valteau-Couanet D; Holmes K; Di Cataldo A; Brichard B; Mosseri V; Marquez C; Plantaz D; Boni L; Michon J
    J Clin Oncol; 2011 Feb; 29(4):449-55. PubMed ID: 21172879
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Meta-analysis of neuroblastomas reveals a skewed ALK mutation spectrum in tumors with MYCN amplification.
    De Brouwer S; De Preter K; Kumps C; Zabrocki P; Porcu M; Westerhout EM; Lakeman A; Vandesompele J; Hoebeeck J; Van Maerken T; De Paepe A; Laureys G; Schulte JH; Schramm A; Van Den Broecke C; Vermeulen J; Van Roy N; Beiske K; Renard M; Noguera R; Delattre O; Janoueix-Lerosey I; Kogner P; Martinsson T; Nakagawara A; Ohira M; Caron H; Eggert A; Cools J; Versteeg R; Speleman F
    Clin Cancer Res; 2010 Sep; 16(17):4353-62. PubMed ID: 20719933
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prognostic value of MYCN and ID2 overexpression in neuroblastoma.
    Alaminos M; Gerald WL; Cheung NK
    Pediatr Blood Cancer; 2005 Dec; 45(7):909-15. PubMed ID: 16047351
    [TBL] [Abstract][Full Text] [Related]  

  • 35. International consensus for neuroblastoma molecular diagnostics: report from the International Neuroblastoma Risk Group (INRG) Biology Committee.
    Ambros PF; Ambros IM; Brodeur GM; Haber M; Khan J; Nakagawara A; Schleiermacher G; Speleman F; Spitz R; London WB; Cohn SL; Pearson AD; Maris JM
    Br J Cancer; 2009 May; 100(9):1471-82. PubMed ID: 19401703
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Percentage tumor necrosis following chemotherapy in neuroblastoma correlates with MYCN status but not survival.
    Bomken S; Davies B; Chong L; Cole M; Wood KM; McDermott M; Tweddle DA
    Pediatr Hematol Oncol; 2011 Mar; 28(2):106-14. PubMed ID: 21214410
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Enlarged and prominent nucleoli may be indicative of MYCN amplification: a study of neuroblastoma (Schwannian stroma-poor), undifferentiated/poorly differentiated subtype with high mitosis-karyorrhexis index.
    Kobayashi C; Monforte-Munoz HL; Gerbing RB; Stram DO; Matthay KK; Lukens JN; Seeger RC; Shimada H
    Cancer; 2005 Jan; 103(1):174-80. PubMed ID: 15549714
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Functional interplay between MYCN, NCYM, and OCT4 promotes aggressiveness of human neuroblastomas.
    Kaneko Y; Suenaga Y; Islam SM; Matsumoto D; Nakamura Y; Ohira M; Yokoi S; Nakagawara A
    Cancer Sci; 2015 Jul; 106(7):840-7. PubMed ID: 25880909
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tumor lysis syndrome, neuroblastoma, and correlation between serum lactate dehydrogenase levels and MYCN-amplification.
    Kushner BH; LaQuaglia MP; Modak S; Cheung NK
    Med Pediatr Oncol; 2003 Jul; 41(1):80-2. PubMed ID: 12764755
    [No Abstract]   [Full Text] [Related]  

  • 40. Neuroblastomas with discordant genotype-phenotype relationships: report of four cases with MYCN amplification and favorable histology.
    Nakagawa A; Matsuoka K; Okita H; Iwafuchi H; Hori H; Kumagai M
    Pediatr Dev Pathol; 2011; 14(2):87-92. PubMed ID: 21288077
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.